Cargando…

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus

AIMS: As metabolic remodeling is a pathological characteristic in type 2 diabetes (T2D), we investigate the roles of newly developed long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide and liraglutide on metabolic remodeling in patients with recent-onset T2D. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Juan, Xi, Liuqing, Zhang, Zhongxiao, Ge, Xiaoxu, Li, Wenyi, Peng, Wenfang, Jiang, Xiaohong, Liu, Wen, Zhao, Nan, Wang, Xingyun, Guo, Xirong, Huang, Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846071/ https://www.ncbi.nlm.nih.gov/pubmed/36686441 http://dx.doi.org/10.3389/fendo.2022.1097612

Ejemplares similares

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

Circulating Ism1 Reduces the Risk of Type 2 Diabetes but not Diabetes-Associated NAFLD
por: Wang, Jiajia, et al.
Publicado: (2022)

Dynamics of the Ethanolamine Glycerophospholipid Remodeling Network
por: Zhang, Lu, et al.
Publicado: (2012)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
por: Huang, Jinxin, et al.
Publicado: (2023)

Long-term menopause exacerbates vaginal wall support injury in ovariectomized rats by regulating amino acid synthesis and glycerophospholipid metabolism
por: Yu, Xia, et al.
Publicado: (2023)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus
por: Taheri, Saeed, et al.
Publicado: (2019)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

A Case of Dulaglutide-Induced Vaginal Bleed
por: Vaccaro, Christopher J, et al.
Publicado: (2023)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
por: Kim, Youngsook, et al.
Publicado: (2022)

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
por: Jain, Akshay B., et al.
Publicado: (2020)

Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells
por: Hishikawa, Daisuke, et al.
Publicado: (2014)

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
por: Dardano, Angela, et al.
Publicado: (2022)

Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report
por: Khan, Abu baker, et al.
Publicado: (2023)

A Case Report of a Pregnant Woman With Type 2 Diabetes Mellitus Using Dulaglutide During the First Trimester of Pregnancy
por: Alghamdi, Adel, et al.
Publicado: (2023)

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
por: Tanaka, Kenichi, et al.
Publicado: (2022)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Brown Adipose Transplantation Improves Polycystic Ovary Syndrome-Involved Metabolome Remodeling
por: Yao, Lihua, et al.
Publicado: (2021)

Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide
por: Babajide, Oyedotun, et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Sanada, Junpei, et al.
Publicado: (2021)

Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity
por: Caputo, Marina, et al.
Publicado: (2021)

The Effect of Liraglutide on Weight Loss in Women with Polycystic Ovary Syndrome: An Observational Study
por: Rasmussen, Christina B., et al.
Publicado: (2014)

Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes
por: Tan, Yijiong, et al.
Publicado: (2022)

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
por: Nagaike, Hiroe, et al.
Publicado: (2019)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level
por: Shahbazi, Mohammad, et al.
Publicado: (2023)

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
por: Hansen, Christian Stevns, et al.
Publicado: (2019)

Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes
por: Wu, Hao, et al.
Publicado: (2023)

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
por: Alatorre, Carlos, et al.
Publicado: (2017)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

FGF21 Serum Levels in the Early Second Trimester Are Positively Correlated With the Risk of Subsequent Gestational Diabetes Mellitus: A Propensity-Matched Nested Case-Control Study
por: Wang, Zhiheng, et al.
Publicado: (2021)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
por: Chang, Kai-Cheng, et al.
Publicado: (2020)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Vemulapalli, Hema Srikanth, et al.
Publicado: (2023)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report
por: Wu, Shengjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5gci32o38tvh7ujmulgjlbcm9h